SCHEMBL1458633

SCHEMBL1458633

Cc1cc(N)n2nc(-c3ccc(B(O)O)cc3Cl)cc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
NPC1 O15118 5/20 0.52
RAB9A P51151 5/20 0.52
HPGD P15428 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NFKB1 P19838 1/20 0.52
HTT P42858 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
KDM4E B2RXH2 5/20 0.48
MAPT P10636 4/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PKM P14618 1/20 0.48
CDK5 Q00535 1/20 0.48
CDK5R1 Q15078 1/20 0.48
DPP4 P27487 9/20 0.43
DPP8 Q6V1X1 6/20 0.43
DPP9 Q86TI2 5/20 0.43
CYP2C19 P33261 2/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4146833 0.81 NPC1 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1458499 0.78 NPC1 (0.54) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL4151815 0.67 ALDH1A1 (0.74) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL5382159 0.67 DPP4 (0.51) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL5381153 0.66 DPP4 (0.53) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL10388599 0.66 KDM4E (0.66) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL10236246 0.65 NPC1 (1.00) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL23447727 0.64 ALDH1A1 (0.63) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL21775853 0.64 DPP4 (0.51) ALDH1A1NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL21775466 0.64 DPP4 (0.51) NPC1RAB9ADPP4DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2480556-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011036128-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
US-20110070190-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110070190-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, RTF2, HCCS ALDH1A1 736/4885NPC1 979/4885RAB9A 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.